PAS
BIO icon

Park Avenue Securities’s Bio-Rad Laboratories Class A BIO Stock Holding History

Park Avenue Securities’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$663K Sell
2,256
-102
-4% -$28.9K ﹤0.01% 1160
2026
Q1 		$657K Sell
2,358
-58
-2% -$16.7K 0.01% 991
2025
Q4 		$732K Sell
2,416
-157
-6% -$49K 0.01% 938
2025
Q3 		$721K Buy
2,573
+252
+11% +$68.6K 0.01% 1014
2025
Q2 		$560K Sell
2,321
-70
-3% -$16.5K 0.01% 1016
2025
Q1 		$582K Buy
2,391
+100
+4% +$30.1K 0.01% 802
2024
Q4 		$753K Buy
2,291
+504
+28% +$171K 0.01% 893
2024
Q3 		$598K Sell
1,787
-377
-17% -$120K 0.01% 911
2024
Q2 		$591K Sell
2,164
-56
-3% -$16.3K 0.01% 892
2024
Q1 		$768K Buy
2,220
+205
+10% +$67.4K 0.01% 785
2023
Q4 		$651K Sell
2,015
-1,578
-44% -$495K 0.01% 800
2023
Q3 		$1.29M Buy
+3,593
New +$1.39M 0.02% 464
2023
Q1 		– Sell
-3,067
Closed -$1.29M – 749
2022
Q4 		$1.29M Buy
3,067
+298
+11% +$120K 0.02% 419
2022
Q3 		$1.16M Buy
2,769
+175
+7% +$87.3K 0.02% 404
2022
Q2 		$1.28M Buy
2,594
+342
+15% +$178K 0.02% 381
2022
Q1 		$1.27M Sell
2,252
-57
-2% -$34.4K 0.02% 399
2021
Q4 		$1.75M Buy
2,309
+33
+1% +$24.7K 0.03% 302
2021
Q3 		$1.7M Buy
2,276
+85
+4% +$63.7K 0.03% 276
2021
Q2 		$1.41M Buy
2,191
+108
+5% +$65.7K 0.03% 294
2021
Q1 		$1.19M Buy
2,083
+568
+37% +$336K 0.03% 295
2020
Q4 		$883K Buy
1,515
+122
+9% +$69.5K 0.02% 321
2020
Q3 		$718K Buy
1,393
+169
+14% +$85.6K 0.02% 305
2020
Q2 		$553K Buy
1,224
+407
+50% +$180K 0.02% 371
2020
Q1 		$286K Buy
817
+117
+17% +$43K 0.02% 244
2019
Q4 		$259K Buy
+700
New +$247K 0.01% 504

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Park Avenue Securities's BIO Position: Q2 2026 in Review

Park Avenue Securities reduced its Bio-Rad Laboratories Class A (BIO) stake by 4.3% in Q2 2026, selling an estimated $28.9K and leaving 2,256 shares worth $663K. The position accounts for ﹤0.01% of the portfolio, ranked #1160.

Park Avenue Securities first reported a position in BIO in Q4 2019 and has held it in 25 quarters since. The position peaked at $1.75M in Q4 2021. 399 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Park Avenue Securities held 2,256 shares of Bio-Rad Laboratories Class A worth $663K as of Q2 2026.
  • Park Avenue Securities sold 102 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $28.9K.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Park Avenue Securities's portfolio in Q2 2026, its #1160 holding.
  • Park Avenue Securities first reported a position in Bio-Rad Laboratories Class A in Q4 2019 and has held it in 25 quarters since.
  • Park Avenue Securities's Bio-Rad Laboratories Class A position peaked at $1.75M in Q4 2021.
  • 399 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Park Avenue Securities's 13F filing for Q2 2026, filed 20 Jul 2026.